Document is current
Any future updates will be listed below
-
Authors
Miao, Hongzhi
Chen, Dong
Ropa, James https://orcid.org/0000-0001-6120-1859
Purohit, Trupta
Kim, EunGi
Sulis, Maria-Luisa
Ferrando, Adolfo https://orcid.org/0000-0002-6212-8574
Cierpicki, Tomasz https://orcid.org/0000-0003-2058-0658
Grembecka, Jolanta https://orcid.org/0000-0002-6180-9095
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1R01CA160467)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1R01CA272561)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA244254)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K99 HL166790)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1R01 CA226759)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1R01 CA282082)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Leukemia and Lymphoma Society (6649-23)
Alex's Lemonade Stand Foundation for Childhood Cancer (22-25561)
U.S. Department of Health & Human Services | NIH | Center for Scientific Review (F31 HL160072)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
- License Information
-
More Information
Article History
Received: 15 January 2024
Revised: 9 June 2024
Accepted: 11 June 2024
First Online: 18 June 2024
Competing interests
: The authors declare the following competing financial interest(s): JG and TC received research support from Kura Oncology, Inc. They have also served as consultants for Kura Oncology, have equity ownership in the company and are co-inventors on patent applications covering MI-3454. Kura Oncology, Inc. and University of Michigan have filed patent applications covering MI-3454 and they hold intellectual property rights on this compound. HM is co-inventor on patent applications covering MI-3454 or related compounds, which were licensed by Kura Oncology. JG, TC and HM receive royalties from the University of Michigan on the patents covering menin inhibitors that were licensed to Kura Oncology. AF is an employee of Regeneron Pharmaceuticals. Other co-authors declare no potential conflict of interest.
